Assess whether the primary endpoint will survive FDA scrutiny (331656)

SITUATION Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on the primary endpoint will because a site-change that invalidates stability claims put advisory-committee question list that exposes a weak secondary endpoint in play. CMC change-control owner should say what advisory-committee question list that exposes a weak secondary endpoint proves.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population. 2. Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after a site-change that invalidates stability claims; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for CMC change-control owner in a mid-size sponsor after a complete response letter. 4. Advisory-committee question list that exposes a weak secondary endpoint is missing the fact CMC change-control owner needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in advisory-committee question list that exposes a weak secondary endpoint, then the action for CMC change-control owner - Hypothesis scorecard against advisory-committee question list that exposes a weak secondary endpoint: supported / rejected / untestable - Missing page in advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims, if any - Regulatory or exam hook Pharmacovigilance would cite